Core Insights - Wu Yizhen, the chairwoman of Meiya Biotechnology Group, transitioned from finance to biotechnology, driven by personal experiences with cancer treatment [1][2] - Meiya Group focuses on autologous stem cells and immune cells, aiming to advance research and applications in the health industry [2] - The company has received strong support from government initiatives, which have facilitated its growth and operational efficiency [2] Group 1: Company Background - Meiya Biotechnology Group was founded in 2012, with its headquarters in Beijing, marking the beginning of its entrepreneurial journey [1] - The company has evolved into a high-tech enterprise centered on cutting-edge biotechnology research and applications [2] - Meiya Group's subsidiary, Beijing Science City Daily Chemical Co., is working on developing its own brand based on biotechnology and green environmental practices [2] Group 2: Industry Context - The biotechnology sector is increasingly recognized for its potential in cancer treatment, moving beyond traditional chemotherapy and radiotherapy to include biological therapies [1] - There is a growing consumer preference for domestic brands, driven by enhanced cultural confidence, which benefits companies like Meiya Group [2] - The government has implemented various supportive policies for Taiwanese entrepreneurs, fostering a conducive environment for cross-strait economic exchanges [3]